

**Amendments to the Specification:**

Please replace the paragraph beginning at page 10, line 9, with the following rewritten paragraph:

--For combinatorial libraries limited to amino acids, the amino acid residue containing at least one S wherein the said S is protected by an orthogonal S-protecting group can be an L- or D-3-mercapto amino acid, including but not limited to L- or D-cysteine or L- or D-penicillamine. For combinatorial libraries including amino acid residues and mimics of amino acid residues, the residue containing at least one S wherein the said S is protected by an orthogonal S-protecting group can be an L- or D-3-mercapto amino acid, including but not limited to L- or D-cysteine or L- or D-penicillamine; 3-mercapto phenylalanine; 2-mercaptoacetic acid; 3-mercaptopropionic acid; 2-mercaptopropionic acid; 3-mercapto-3,3,-dimethyl propionic acid; 3-mercapto-3,3,-diethyl propionic acid; 3-mercapto,3-methyl propionic acid; 2-mercapto,2-methyl acetic acid; ~~3-cyclopentamethylene,3-mercaptopropionic acid; or 2-cyclopentamethylene,2-mercaptoacetic acid~~ 3-cyclopentamethylene,3-mercaptopropionic acid; or 2-cyclopentamethylene,2-mercaptoacetic acid.--

Please amend Table 1 beginning on Page 39 (line 1) (Table entry PL-1649) as follows:

TABLE 1 Melanocortin Receptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off ( $\mu$ M)	MC4-R	MC1-R (B-16)
PL-1582	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Cys-L-Arg-L-Trp-NH <sub>2</sub>	1	66	93
PL-1583	ReO[V]	Ac-L-Nle-L-Ala-L-His-L-Cys-D-Phe-L-Arg-L-Trp-NH <sub>2</sub>	1	75	84
PL-1584	ReO[V]	Ac-L-Nle-L-His-L-Cys-L-His-D-Phe-L-Arg-L-Trp-NH <sub>2</sub>	1	71	96
PL-1585	ReO[V]	Ac-L-Nle-L-Ala-L-His-L-Phe-L-Cys-L-Arg-L-Trp-NH <sub>2</sub>	1	22	45
PL-1587	ReO[V]	Ac-L-Nle-L-Arg-L-Arg-D-Nal 2-L-Cys-L-Trp-NH <sub>2</sub>	1	98	96
PL-1592	ReO[V]	Ac-L-Nle-L-Ala-L-Arg-L-His-D-Phe-L-Cys-L-Trp-NH <sub>2</sub>	1	7	19
PL-1593	ReO[V]	Ac-L-Nle-L-Ala-D-Arg-L-His-D-Phe-L-Cys-L-Trp-NH <sub>2</sub>	1	16	71
PL-1594	ReO[V]	Ac-L-Nle-L-Ala-L-His-D/L-Atc-L-Arg-L-Cys-L-Trp-NH <sub>2</sub>	1	24	100
PL-1595	ReO[V]	Ac-L-Nle-L-Ala-L-His-Aic-L-Arg-L-Cys-L-Trp-NH <sub>2</sub> (SEQ ID NO:49)	1	3	60
PL-1597	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D/L-Atc-L-Cys-L-Trp-NH <sub>2</sub>	1	11	68
PL-1598	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Qal(2')-L-Cys-L-Trp-NH <sub>2</sub>	1	9	22
PL-1605	ReO[V]	Ac-L-Nle-L-Arg-L-Arg-D-Nal 2-L-Cys-L-Trp-NH <sub>2</sub>	1	100	100
PL-1606	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-Aic-L-Cys-L-Trp-NH <sub>2</sub> (SEQ ID NO:50)	1	63	44
PL-1607	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Qal(2')-L-Arg-L-Cys-L-Trp-NH <sub>2</sub>	1	52	100
PL-1621	ReO[V]	Ac-L-Nle-L-Ala-L-His-Achc-L-Arg-L-Cys-L-Trp-NH <sub>2</sub> (SEQ ID NO:51)	1	34	36
PL-1623	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Sal-L-Arg-L-Cys-L-Trp-NH <sub>2</sub>	1	55	92
PL-1624	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Sal-L-Cys-L-Trp-NH <sub>2</sub>	1	48	25
PL-1626	ReO[V]	Ac-L-Nle-L-Arg-L-Trp-D-Nal 2-L-Cys-L-Trp-NH <sub>2</sub>	1	54	66
PL-1633	ReO[V]	Ac-L-Nle-D-Arg-L-Arg-D-Nal 2-L-Cys-L-Trp-NH <sub>2</sub>	1	87	86
PL-1633	ReO[V]	Ac-L-Nle-D-Arg-L-Arg-D-Nal 2-L-Cys-L-Trp-NH <sub>2</sub>	1	87	91
PL-1634	ReO[V]	Ac-L-Nle-L-Arg-D-Arg-D-Nal 2-L-Cys-L-Trp-NH <sub>2</sub>	1	50	42
PL-1635	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-Acpc-L-Cys-L-Trp-NH <sub>2</sub> -NH <sub>2</sub> (SEQ ID NO:52)	1	43	14
PL-1636	ReO[V]	Ac-L-Nle-L-Ala-L-His-Acpc-L-Arg-L-Cys-L-Trp-NH <sub>2</sub> (SEQ ID NO:53)	1	38	20
PL-1638	ReO[V]	Ac-L-Nle-L-Arg-L-Arg-D-Qal(2')-L-Cys-L-Trp-NH <sub>2</sub>	1	48	67
PL-1649	ReO[V]	Ac-L-His-Gly-Gly-L-Cys-L-Trp-NH <sub>2</sub> (SEQ ID NO:54)	10	62	19
PL-1650	ReO[V]	Ac-L-His-D-Phe-L-Arg-L-Cys-L-Trp-NH <sub>2</sub>	10	66	52
PL-1651	ReO[V]	Ac-L-His-D-Phe-D-Arg-L-Cys-L-Trp-NH <sub>2</sub>	10	58	95
PL-1652	ReO[V]	Ac-L-His-L-Phe-D-Arg-L-Cys-L-Trp-NH <sub>2</sub>	10	40	11
PL-1655	ReO[V]	Ac-L-His-L-Phe-L-Arg-L-Cys-L-Trp-NH <sub>2</sub> (SEQ ID NO:8)	10	51	45
PL-1658	ReO[V]	Ac-L-Nle-L-Arg-L-Arg-D-Phe(3,4-diCl)-L-Cys-L-Trp-NH <sub>2</sub>	1	100	99

Please amend Table 1 beginning on Page 41 (line 1) as follows:

TABLE 1 Melanocortin Receptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1730	ReO[V]	Ac-L-Nle-L-Arg-L-Nal 1-D-Phe(4-Cl)-L-Cys-NH <sub>2</sub>	1	35	39
PL-1731	ReO[V]	Ac-L-Nle-L-Arg-L-Nal 2-D-Phe(4-Cl)-L-Cys-NH <sub>2</sub>	1	63	38
PL-1732	ReO[V]	Ac-L-Nle-L-Arg-L-Trp-D-Phe(4-Cl)-L-Cys-NH <sub>2</sub>	1	74	53
PL-1733	ReO[V]	L-Tic-D-Phe(4-Cl)-L-Cys-NH <sub>2</sub>	1	8	14
PL-1734	ReO[V]	L-Tic-D-Phe(4-Cl)-L-Trp-L-Cys-NH <sub>2</sub>	1	7	6
PL-1735	ReO[V]	L-Tic-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	13	12
PL-1736	ReO[V]	Ac-D-Ala-L-His-L-Cys-D-(N-Bzl)Phe-L-Arg-L-Trp-NH <sub>2</sub>	1	3	6
PL-1737	ReO[V]	Ac-D-Ala-L-His-L-Cys-L-(N-Bzl)Phe-L-Arg-L-Trp-NH <sub>2</sub>	1	3	48
PL-1738	ReO[V]	Ac-D-Ala-L-His-L-Cys-D-(N-Bzl)Nal 2-L-Arg-L-Trp-NH <sub>2</sub>	1	23	13
PL-1751	ReO[V]	Ac-L-His-L-(N-2'naphthalene)Phe-L-Arg-L-Trp-L-Cys-NH <sub>2</sub> (SEQ ID NO:55) <u>Ac-L-His-L-(N-2'naphthalene)Phe-L-Arg-L-Trp-L-Cys-NH<sub>2</sub> (SEQ ID NO:55)</u>	1	70	78
PL-1752	ReO[V]	Ac-D-Ala-L-His-L-Cys-L-(N-2'naphthalene)Phe-L-Arg-L-Trp-NH <sub>2</sub> <u>Ac-D-Ala-L-His-L-Cys-L-(N-2'naphthalene)Phe-L-Arg-L-Trp-NH<sub>2</sub></u>	1	5	29
PL-1753	ReO[V]	Ac-D-Ala-L-His-L-Cys-D-(N-2'naphthalene)Phe-L-Arg-L-Trp-NH <sub>2</sub> <u>Ac-D-Ala-L-His-L-Cys-D-(N-2'naphthalene)Phe-L-Arg-L-Trp-NH<sub>2</sub></u>	1	22	50
PL-1754	ReO[V]	D-Tic-D-Phe(4-Cl)-L-Trp-L-Cys-NH <sub>2</sub>	1	7	4
PL-1755	ReO[V]	Ac-L-Arg-L-Lys-L-Phe-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	40	48
PL-1756	ReO[V]	Ac-L-Nle-L-Lys-L-Phe-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	63	64
PL-1757	ReO[V]	Ac-L-Arg-L-Lys-L-Leu-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	45	38
PL-1758	ReO[V]	Ac-L-Nle-L-Lys-L-Leu-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	94	78
PL-1759	ReO[V]	Ac-L-Arg-L-Phe-L-Lys-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	62	61
PL-1760	ReO[V]	Ac-L-Nle-L-Phe-L-Lys-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	72	84
PL-1761	ReO[V]	Ac-L-Arg-L-Leu-L-Lys-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	16	51
PL-1762	ReO[V]	Ac-L-Nle-L-Leu-L-Lys-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	69	82
PL-1774	ReO[V]	Ac-L-Nle-L-Lys-L-Val-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	83	79
PL-1775	ReO[V]	Ac-L-Nle-L-Lys-L-Ile-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	78	57
PL-1776	ReO[V]	Ac-L-Nle-L-Lys-L-Nle-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	76	33
PL-1777	ReO[V]	Ac-L-Nle-L-Lys-L-Thr-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	79	86
PL-1778	ReO[V]	Ac-L-Nle-L-Lys-L-Tle-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	89	60
PL-1779	ReO[V]	Ac-L-Nle-L-Lys-L-Chg-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	85	71
PL-1780	ReO[V]	Ac-L-Nle-L-Lys-L-Cha-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	77	34

Please amend Table 1 beginning on Page 44 (line 1) as follows:


TABLE 1 Melanocortin Receptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1844	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Trp-D-Cys-L-Trp-NH <sub>2</sub>	1	83	98
PL-1845	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Trp-L-Cys-D-Trp-NH <sub>2</sub>	1	96	99
PL-1846	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Cys-L-Trp-NH <sub>2</sub>	0.1	4	85
PL-1849	ReO[V]	C <sub>6</sub> H <sub>5</sub> -CO-L-Lys-D-Phe-L-Cys-L-Trp-NH <sub>2</sub>	1	12	39
PL-1850	ReO[V]	C <sub>6</sub> H <sub>5</sub> -CH=CH-CO-L-Lys-D-Phe-L-Cys-L-Trp-NH <sub>2</sub>	1	-2	24
PL-1851	ReO[V]	Pyridine-3-CO-L-Lys-D-Phe-L-Cys-L-Trp-NH <sub>2</sub>	1	-5	26
PL-1852	ReO[V]	Tetralin-2-CO-L-Lys-D-Phe-L-Cys-L-Trp-NH <sub>2</sub>	1	0	15
PL-1853	ReO[V]	Naphthalene-1-CO-L-Lys-D-Phe-L-Cys-L-Trp-NH <sub>2</sub>	1	9	27
PL-1854	ReO[V]	Naphthalene-2-CO-L-Lys-D-Phe-L-Cys-L-Trp-NH <sub>2</sub>	1	-6	24
PL-1855	ReO[V]	Lys(Z)-Gly-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	0	32
PL-1856	ReO[V]	Lys(Z)-L-Val-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	31	53
PL-1857	ReO[V]	Lys(Z)-L-Nle-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	32	40
PL-1858	ReO[V]	Lys(Z)-L-Leu-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	31	36
PL-1859	ReO[V]	Ac-L-Phe-L-Phe-L-Cys-L-Tic-L-Lys-NH <sub>2</sub> (SEQ ID NO:64)	1	-8	9
PL-1860	ReO[V]	Ac-L-Phe-L-Phe-L-Cys-L-Inp-L-Lys-NH <sub>2</sub> (SEQ ID NO:65)	1	0	6
PL-1861	ReO[V]	Ac-L-Phe-L-Phe-L-Cys-4-Abz-L-Lys-NH <sub>2</sub> (SEQ ID NO:66)	1	-14	0
PL-1862	ReO[V]	Ac-L-Phe-L-Phe-L-Cys-3-Abz-L-Lys-NH <sub>2</sub> (SEQ ID NO:67)	1	-7	17
PL-1863	ReO[V]	Ac-L-Phe-L-Phe-L-Cys-2-Abz-L-Lys-NH <sub>2</sub> (SEQ ID NO:68)	1	6	19
PL-1864	ReO[V]	Ac-L-Phe-D-Trp-L-Cys-2-Abz-L-Lys-NH <sub>2</sub>	1	-7	17
PL-1865	ReO[V]	Ac-L-Ser(Bzl)-D-Phe(2-Cl)-L-Arg-D-Trp-L-Cys-NH <sub>2</sub>	1	40	13
PL-1866	ReO[V]	Bz-L-Ser(Bzl)-D-Phe(2-Cl)-L-Arg-D-Trp-L-Cys-NH <sub>2</sub>	1	30	16
PL-1867	ReO[V]	Heptanoyl-L-Asn-D-Phe(2-Cl)-L-Arg-D-Trp-L-Cys-NH <sub>2</sub>	1	60	52
PL-1868	ReO[V]	Heptanoyl-L-Asp-D-Phe(2-Cl)-L-Arg-D-Trp-L-Cys-NH <sub>2</sub>	1	-3	5
PL-1869	ReO[V]	Heptanoyl-L-Lys(NH-Bz)-D-Phe(2-Cl)-L-Arg-D-Trp-L-Cys-NH <sub>2</sub>	1	42	25
PL-1870	ReO[V]	Heptanoyl-D-B-Hphe(4-F)-L-Arg-D-Trp-L-Cys-NH <sub>2</sub>	1	11	12
PL-1871	ReO[V]	Heptanoyl-D-B-Hphe(2-Cl)-L-Arg-D-Trp-L-Cys-NH <sub>2</sub>	1	3	10
PL-1872	ReO[V]	Ac-D-Ala-L-His-L-Cys-D-Phe(2-Cl)-L-Arg-L-Trp-NH <sub>2</sub>	1	79	27
PL-1873	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-D-Cys-Trp-NH <sub>2</sub>	1	31	92.6
PL-1874	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Trp-D-Cys-D-Trp-NH <sub>2</sub>	1	90	98
PL-1875	ReO[V]	<del>1-Naphthlene-acetyl-L-Lys-L-Ala-D-Phe(4-Cl)-L-Cys-Trp-NH<sub>2</sub></del> 1-Naphthalene-acetyl-L-Lys-L-Ala-D-Phe(4-Cl)-L-Cys-Trp-NH <sub>2</sub>	1	77	34
PL-1876	ReO[V]	<del>2-Naphthlene-acetyl-L-Lys-L-Ala-D-Phe(4-Cl)-L-Cys-Trp-NH<sub>2</sub></del> 2-Naphthalene-acetyl-L-Lys-L-Ala-D-Phe(4-Cl)-L-Cys-Trp-NH <sub>2</sub>	1	52	8
PL-1877	ReO[V]	3-Bromophenyl acetyl-L-Lys-L-Ala-D-Phe(4-I)-L-Cys-Trp-NH <sub>2</sub>	1	92	31

Please amend Table 1 beginning on Page 46 (line 1) as follows:

TABLE 1 Melanocortin Receptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1905	ReO[V]	2-Chlorophenyl acetyl-L-Lys-L-Ala-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	86	31
PL-1906	ReO[V]	4-Chlorophenyl acetyl-L-Lys-L-Ala-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	91	68
PL-1907	ReO[V]	4-Methylphenyl acetyl-L-Lys-L-Ala-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	69	44
PL-1908	ReO[V]	Indonyl acetyl-L-Lys-L-Ala-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	33	8
PL-1909	ReO[V]	3-Bromophenyl acetyl-L-Arg-L-Ala-D-Phe(4-Cl)-L-Cys-L-Trp-NH <sub>2</sub>	1	95	32
PL-1910	ReO[V]	Heptanoyl-L-Dpr(Bz)-D-Phe(2-Cl)-L-Arg-D-Trp-L-Cys-NH <sub>2</sub>	1	23	42
PL-1911	ReO[V]	Heptanoyl-L-Dpr(2'-Naphthylene acetyl 2'-Naphthalene acetyl)-D-Phe(2-Cl)-L-Arg-D-Trp-L-Cys-NH <sub>2</sub>	1	-6	11
PL-1912	ReO[V]	Heptanoyl-L-Dpr(1'-Adamantane carbonyl 1'-Adamantane carbonyl)-D-Phe(2-Cl)-L-Arg-D-Trp-L-Cys-NH <sub>2</sub>	1	-3	2
PL-1913	ReO[V]	Heptanoyl-L-Dpr(4'-MePhenyl acetyl)-D-Phe(2-Cl)-L-Arg-D-Trp-L-Cys-NH <sub>2</sub>	1	22	35
PL-1914	ReO[V]	Heptanoyl-L-Dpr(3'-BrPhenyl acetyl)-D-Phe(2-Cl)-L-Arg-D-Trp-L-Cys-NH <sub>2</sub>	1	20	53
PL-1915	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(2-Cl)-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	94	72
PL-1916	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(2-Cl)-L-Arg-L-His-L-Cys-NH <sub>2</sub>	1	9	44
PL-1917	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(2-Cl)-L-Arg-L-Nal 2'-L-Cys-NH <sub>2</sub>	1	94	48
PL-1918	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(2-Cl)-L-Arg-L-Bip-L-Cys-NH <sub>2</sub>	1	10	21
PL-1919	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(2-Cl)-L-Arg-L-Pal 3'-L-Cys-NH <sub>2</sub>	1	17	47
PL-1920	ReO[V]	D-Phe-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	52	65
PL-1921	ReO[V]	Ac-D-Phe-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	20	25
PL-1922	ReO[V]	Ac-L-Nle-D-Phe-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	25	28
PL-1923	ReO[V]	Ac-L-Nle-L-Ala-D-Phe-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	68	70
PL-1924	ReO[V]	Ac-L-Pro-D-Phe-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	44	33
PL-1925	ReO[V]	Heptanoyl-D-Phe-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	6	18
PL-1926	ReO[V]	Bz-L-Arg-L-Trp-L-Cys-NH <sub>2</sub> (SEQ ID NO:69)	1	7	25
PL-1927	ReO[V]	Phenyl acetyl-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	8	28
PL-1928	ReO[V]	3-Phenyl-propanoyl-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	8	32
PL-1929	ReO[V]	4-Phenyl-butanoyl-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	2	18
PL-1930	ReO[V]	t-Cinnamoyl-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	-20	9
PL-1931	ReO[V]	1-Naphthyl-acetyl-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	10	92	47
PL-1932	ReO[V]	2-Naphthyl-acetyl-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	1	16
PL-1933	ReO[V]	1-Naphthoyl-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	0	14
PL-1934	ReO[V]	2-Naphthoyl-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	6	34
PL-1935	ReO[V]	Heptanoyl-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	8	39
PL-1936	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(4-F)-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	81	71
PL-1937	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(penta-F)-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	91	65
PL-1938	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Pal(2)-L-Arg-L-Trp-L-Cys-NH <sub>2</sub>	1	16	16

Please replace the paragraph beginning at page 56, line 37, with the following rewritten paragraph:

--The library design was based on the tetrapeptide message sequence, His-Phe-Arg-Trp (6-9 sequence) (SEQ ID NO:1), of  $\alpha$ -MSH. This sequence exists as a reverse turn, making it suitable for conversion into a metallopeptide format of this invention. In this approach metalloptides were designed around a tripeptide  $N_3S_1$  MBD designed for a rhenium metal ion. The MBD was derivatized to yield the pentapeptide Ac-His-Phe-Arg-Cys-Trp-NH<sub>2</sub> (SEQ ID NO:8) as a putative candidate for melanocortin ("MC") receptors. Further refinements in the structure were made in response to other considerations, including the chirality of amino acid side chains, yielding a template structure Ac-His-D-Phe-Arg-Cys-Trp-NH<sub>2</sub>. The structure of this peptide after binding to rhenium is:



--